Park Medi World Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Strong volume-led quarter, margin steady: Revenue grew 18% YoY driven by patient volumes and ramp-up of acquired hospitals, while nine-month EBITDA margin held at 26% despite integration costs.
• Aggressive bed expansion underway: 660 beds added in FY26 alone (Agra 360, Panchkula 300), with a pipeline targeting ~5,260 beds by FY28 and a long-term aspiration to double to ~10,000.
• CGHS rate hike is a material, lagged tailwind: A 12–15% hike benefits Park disproportionately given its ~83% government payer mix, but full financial impact will only reflect by H2 FY27.
• Balance sheet transforming to debt-free: Term debt reduced from ₹425 cr pre-IPO to ~₹15 cr by end-January, with full repayment planned in February.
• What to watch next quarter: Agra and Panchkula commissioning execution, the pace of CGHS rate hike percolation into revenue, and whether the elevated manpower cost normalizes as new hospitals go live.

Volume & Operating Performance

• Patient volumes the growth engine: IPD plus OPD footfall grew 24% to 6.6 lakhs in nine months, with occupancy rising to 65% even as 250 beds were added at Bathinda, signaling strong demand absorption.
• Case mix deepening, not price-led: ARPOB improved from ₹25,500 to ₹27,400, driven by a shift toward tertiary and quaternary procedures including robotic joint replacement, organ transplant, neurointervention, and cardiac intervention.
• ALOS efficiency: Average length of stay decreased from 6.59 to 6.34 days, reflecting tighter clinical processes and throughput.
• Disallowance best-in-class: Claims disallowance held at 8–9%, the lowest in the industry, versus a 12–15% industry range, attributed to a strong team of super-specialists proactively clarifying queries.
• Mature hospitals leveraged, new ones ramping: Mature hospitals continued to demonstrate operating leverage, while newer and acquired hospitals progressed along the planned ramp-up trajectory.

Sanjay Sharma: "And we have brought down the disallowance to about 8% to 9%, which is the lowest in the industry. Even in TPA insurance and cash, this disallowance is ranging anywhere between 12% to 15%."

Expansion Pipeline & Cluster Strategy

• FY26 bed addition: 660 beds added this year: Agra (360 beds, acquired, commissioning February) and Panchkula (300 beds, greenfield, commissioning March first week).
• FY27 pipeline: 500 beds planned: Kanpur (300) and Delhi (200).
• FY28 pipeline: 850 beds planned: Gorakhpur (400), Ambala Extension Onco (200), Rohtak Greenfield (250), taking total capacity to ~5,260 beds.
• Long-term ambition: Management aspires to double capacity to approximately 10,000 beds in the five years following the FY28 pipeline.
• Cluster density over geographic sprawl: Strategy focuses on dense regional clusters in Haryana, Punjab, Delhi, and Rajasthan, and now Uttar Pradesh, enabling scale with clinical consistency and optimal resource utilization.
• UP pearl-and-necklace model: Three pivots covering the entire span of UP: Agra (west), Kanpur (center), Gorakhpur (east), with Lucknow and Banaras as potential future infill acquisitions.
• Agra as strategic pivot: Agra is the largest micro-market and an important cog in the UP strategy, assessed both as a standalone asset and as a platform for regional expansion.
• Capex efficiency: Blended capex of ₹30–35 lakhs per bed for the next 2,000 beds; brownfield acquisitions target distressed assets at deep discounts, evaluated on strategic location, distress level, local medical services, and headroom to grow.

Management: "Looking at Agra, we looked at Agra asset in two ways. One is as an isolated case, it is the largest micro market. And secondly, we looked at it as also an important cog in the wheel for pushing our UP strategy."

Payer Mix & CGHS Rate Hike

• Government-payer concentration: Government scheme mix stands at 83% of payer mix, with self-pay at 9% and TPA at 8%. Within the government panel, 93% is central government, which management characterizes as sovereign with no default risk.
• CGHS rate hike mechanics: A 12–15% rate hike has been announced, described as one of the most handsome hikes done. Park is the maximum beneficiary given its payer mix, but the hike takes 3–6 months to percolate from CGHS to ECHS, railways, paramilitary, state governments, and other schemes.
• Conservative revenue recognition: Management will conservatively account for a 7.5% increment in revenue and EBITDA from the hike, not the full 12–15% surge, with full impact expected by H2 FY27.
• Receivable cycle improving: Receivables are predominantly central government (sovereign), with a historical turnaround of four and a half months. Management expects this to reduce to four months by FY26-end and toward three and a half months going forward.
• Payer mix not a strategic choice: The 83% government mix is coincidental to the patient demographic, not a deliberate strategy; Park does not select patients by socioeconomic status or payment mechanism.

Sanjay Sharma: "Our focus has been on the affordable side. So, we have been focusing on the bottom and the middle of the pyramid. Largely, the population of 128 crores out of 140 crores, which cannot afford healthcare."

Margin Structure & Cost Dynamics

• Margin stability commitment: Nine-month EBITDA margin of 26% and PAT margin of 17%, with management expecting these levels to hold over the mid-to-long term (3, 5, 10 years) even as bed capacity scales.
• Manpower cost elevated, temporary: Manpower cost appeared elevated in Q3 because hiring was done ahead of Agra and Panchkula commissioning; both hospitals launch with all specialists provisioned on day one.
• Doctor fees step-up explained: An 8% QoQ increase in doctor and consultation fees reflects hiring for Agra and Panchkula, plus a shift toward advanced super-specialty consultants as occupancy reaches 75% at mature hospitals.
• Acquisition ramp-up trajectory: Historical pattern: at 30% occupancy, achieve EBITDA breakeven; next year ~20% EBITDA margin; third year 26–27% margin. Management is confident Agra will follow this trajectory.
• Robotics investment supports margin, not ARPOB: Three fifth-generation da Vinci robots were acquired simultaneously, an unusual industry move. The turnover at affordable cost improves EBITDA margins while keeping ARPOB in the affordable segment.
• Return ratios strong: Annualized ROCE at ~21% and ROE at 23%, with potential for slight improvement going forward.

Sanjay Sharma: "And since the past 21 years, we have been giving this EBITDA of 27% and PAT of 17%. And in coming years, also 10 to 15, 20 years, we expect that our margins will be around this value only."

People & Clinical Model

• Full-time doctor model: All consultants are full-time; no visiting consultant policy. Doctors are evaluated and rewarded solely on patient satisfaction, attendance, and clinical outcomes, not on volume or revenue.
• Graded percentile compensation: Doctors scoring above 90–95 percentile can earn monthly rewards exceeding their base remuneration package, driving high satisfaction and retention.
• Hiring magnetism: Park attracts top clinical talent through four factors: attractive fixed-plus-variable remuneration, high case volumes (75,000 IPD in nine months across 1,200 doctors), early responsibility opportunities, and the industry's most robust relocation and community support for tier-2/3 locations.
• DNB seats awarded: 63 DNB seats received from the government in specialties and super-specialties, strengthening the academic and talent pipeline.
• Wage inflation and attrition unanswered: Management did not provide specific wage inflation guidance or an attrition rate figure when asked by analysts.

Sanjay Sharma: "And if anybody is scoring more than 90, 95 percentile, this reward can even go higher than their remuneration package per month. So there is a great satisfaction level at the consultant level."

Balance Sheet & Capital Allocation

• Near-complete debt repayment: Pre-IPO term debt of ₹425 cr reduced to ~₹15 cr as of January 31, with full repayment planned in February, making the company completely debt-free.
• Capital allocation priorities: Strengthening the balance sheet, funding organic and inorganic expansion, and improving return ratios over the medium term. Incremental capex expected to be largely optimization-led.
• Agra acquisition economics: Acquired for ₹245 cr for 360 beds; pre-acquisition monthly top line was ₹50–60 lakhs to ₹1 cr at 30% occupancy on 180 beds. Post-acquisition, monthly top line is ₹21–23 cr. Management declined to provide annual EBITDA, citing sub-optimal current occupancy.
• Mohali as proof case: Mohali asset had similar capex per bed to Agra and delivered a 36x revenue jump in 30 months, exceeding expectations.

Rajesh Sharma: "So if I talk about as of 31st Jan, the total term debt will stand at close to INR15 crores, which we also plan to repay in Feb. So by end of Feb, we will be completely debt-free company."

Guidance & Commitments

Key Metrics